Australia's most trusted
source of pharma news
Wednesday, 30 October 2024
Posted 1 August 2024 AM
The PBAC is being asked to consider 18 changes to listings at its November meeting, as pharmas seek to add indications, move up the lines and remove combination requirements.
AstraZeneca is seeking a recommendation for Imfinzi in combination with platinum-based chemotherapy, followed by maintenance treatment with or without Lynparza, to treat advanced, metastatic or recurrent endometrial cancer. The combo got an EU nod for endometrial cancer in July.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.